PRISM ALS: New stem cell models to transform research into treatments for MND/ALS
Preview text: PRISM ALS: New stem cell models to transform research into treatments for MND/ALS 96 A…
Image not available
No image available for this email.
- Subject
- PRISM ALS: New stem cell models to transform research into treatments for MND/ALS
- Preview text
- PRISM ALS: New stem cell models to transform research into treatments for MND/ALS 96 A…
- From
- marketing@
axolbio.com - Brand
- Axol Bioscience
- ESP
- HubSpot
- Sent
- Mon Jul 27, 2026, 12:33 PM ET
- Sent to
- United Kingdom (axolbio.co.uk), axolbio.com, United Kingdom (newcells.co.uk)
- Size
- 128 KB
- Images
- 10
- Links
- 15, 7 of them buttons
- Subject length
- 82 characters
Against Axol Bioscience's usual
Sent in the 12 PM hour, which holds 17% of its emails; 50% arrive in the 2 PM hour. The subject is 82 characters; its average is 57.
Email headers
What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.
- From
- Axol Bioscience <[email protected]>
- Reply-To
- [email protected]
- Subject
- PRISM ALS: New stem cell models to transform research into treatments for MND/ALS
- Date
- Mon, 27 Jul 2026 17:33:11 +0100
- Message-ID domain
- bf06x.hubspotemail.net
- Return-Path domain
- bf06x.hubspotemail.net
- DKIM signature
- d=bf06x.hubspotemail.net s=hs1; d=axolbio.com s=hs2-6097189
- List-Unsubscribe
- Present, one-click
- Feedback-ID sender
- HubSpot
Servers it passed through, newest first
- from bid47wr.bf06x.hubspotemail.net [158.247.24.185] by our receiving server with ESMTPS
Other sending headers (names only): X-HS-Cid, X-Report-Abuse-To
Sent just before and after
| Oct 10, 2026 4:23 AM | Thank you for subscribing | |
| Sep 29, 2026 2:43 PM | New human iPSC-derived co-culture systems for more physiologically relevant ALS modeling | |
| Aug 31, 2026 2:24 PM | Retinal toxicity assessment using human iPSC-derived retinal organoids | |
| Jul 27, 2026 12:33 PM | PRISM ALS: New stem cell models to transform research into treatments for MND/ALS (this email) | |
| Jul 11, 2026 12:54 PM | Thank you for subscribing | |
| Jul 2, 2026 2:33 PM | Physiologically relevant human iPSC-derived models and specialist services | |
| Jul 2, 2026 2:16 PM | Thank you for subscribing |